Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-2
- Development stage
- Phase 2
- Lead developer
- Microbial Ecosystem Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
MET-2 (Microbial Ecosystem Therapeutic-2) is an orally administered, encapsulated microbial therapeutic developed by NuBiyota for the treatment of psychiatric disorders, specifically major depressive disorder (MDD) and generalized anxiety disorder (GAD). It consists of a defined consortium of 40 purified, lyophilized bacterial strains derived from the stool of a single healthy donor and grown in a laboratory setting. MET-2 is designed as a safer, more standardized, and less invasive alternative to fecal microbiota transplantation (FMT), targeting the gut-brain axis to modulate mood and anxiety symptoms by restoring a healthy gut microbial ecosystem. The therapeutic aims to shift the recipient's microbiome toward a more balanced state, thereby altering communication pathways between the gut and the brain to alleviate neuropsychiatric symptoms.
- Other names
- Microbial Ecosystem Therapeutic-2Microbial Ecosystem Therapeutic 2
Beyond the preview
Go deeper on MET-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-2.